Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 31 USD -1.71%
Market Cap: 5.1B USD

Alkermes Plc
Investor Relations

Alkermes Plc, an Irish biopharmaceutical company, has carved its niche at the intersection of neuroscience and oncology, a strategic pivot that underscores its commitment to addressing unmet medical needs. The firm's focus lies in the development of innovative pharmaceuticals that offer hope and efficacy where other treatments may fall short. These include proprietary products as well as collaborations with more established pharmaceutical entities. At the heart of Alkermes' operations is its R&D engine, which drives the development of cutting-edge treatments leveraging the company's proprietary technology platforms. This not only underpins its internal drug development pipeline but also enhances its value proposition in collaborations with partner companies, fostering a symbiotic environment where innovation and mutual benefit intersect.

The way Alkermes generates revenue is multifaceted, reflecting its dynamic business model. The company earns through product sales from its proprietary medicines, which are tailored for chronic diseases such as schizophrenia, addiction, and multiple sclerosis. Moreover, a significant portion of its income is derived from strategic collaborations and royalty agreements, where it grants larger pharmaceutical companies access to its technology platforms or the commercial rights to certain drug formulations. These alliances often entail milestone-based payments and ongoing royalties contingent upon sales performance, providing Alkermes with a steady revenue stream and reducing its dependency on the success of any single product. By balancing its own product development with these partnerships, Alkermes secures financial robustness while maintaining its position at the forefront of pharmaceutical innovation.

Show more
Loading

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Richard F. Pops
Chairman & CEO
No Bio Available
Mr. Blair C. Jackson
Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO
No Bio Available
Mr. David Joseph Gaffin J.D.
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
No Bio Available
Mr. Iain Michael Brown
Senior VP & CFO
No Bio Available
Dr. Craig C. Hopkinson M.D.
Executive VP of Research & Development and Chief Medical Officer
No Bio Available
Dr. Floyd E. Bloom M.D.
Founder
No Bio Available
Mr. Samuel J. Parisi
Interim Principal Accounting Officer & VP of Finance
No Bio Available
Mr. Thomas Harvey
Chief Information Officer & Senior VP of IT
No Bio Available
Ms. Sandra Coombs
Senior Vice President of Corporate Affairs & Investor Relations
No Bio Available
Mr. Stephen Schiavo
Senior VP & Chief Human Resources Officer
No Bio Available

Contacts

Address
DUBLIN
DUBLIN
Connaught HSE, 1 Burlington Road
Contacts
+35317728000.0
www.alkermes.com